111 related articles for article (PubMed ID: 1900306)
1. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension.
Sarin SK; Groszmann RJ; Mosca PG; Rojkind M; Stadecker MJ; Bhatnagar R; Reuben A; Dayal Y
J Clin Invest; 1991 Mar; 87(3):1032-6. PubMed ID: 1900306
[TBL] [Abstract][Full Text] [Related]
2. Hyperdynamic circulation in a chronic murine schistosomiasis model of portal hypertension.
Sarin SK; Mosca P; Sabbà C; Groszmann RJ
Hepatology; 1991 Mar; 13(3):581-4. PubMed ID: 1900255
[TBL] [Abstract][Full Text] [Related]
3. Resistance to reinfection in experimental murine schistosomiasis: role of porto-hepatic hemodynamics.
Pons HA; Morgan JS; Hutchinson ML; Rojkind M; Groszmann RJ; Stadecker MJ
Am J Trop Med Hyg; 1989 Aug; 41(2):189-97. PubMed ID: 2505623
[TBL] [Abstract][Full Text] [Related]
4. Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol.
Mies S; Neto OB; Beer A; Baía CE; Alfieri F; Pereira LM; Sette MJ; Raia S
Dig Dis Sci; 1997 Apr; 42(4):751-61. PubMed ID: 9125644
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic mechanisms of emerging portal hypertension caused by schistosomiasis in the hamster.
Morgan JS; Groszmann RJ; Rojkind M; Enriquez R
Hepatology; 1990 Jan; 11(1):98-104. PubMed ID: 2104820
[TBL] [Abstract][Full Text] [Related]
6. Differential immunoregulation of granulomatous inflammation, portal hypertension, and hepatic fibrosis in murine schistosomiasis mansoni.
Olds GR; el Meneza S; Mahmoud AF; Kresina TF
J Immunol; 1989 May; 142(10):3605-11. PubMed ID: 2497177
[TBL] [Abstract][Full Text] [Related]
7. Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol.
Braillon A; Moreau R; Hadengue A; Roulot D; Sayegh R; Lebrec D
J Hepatol; 1989 Nov; 9(3):312-8. PubMed ID: 2607120
[TBL] [Abstract][Full Text] [Related]
8. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
D'Amico M; Mejías M; García-Pras E; Abraldes JG; García-Pagán JC; Fernández M; Bosch J
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(10):G1191-8. PubMed ID: 22403792
[TBL] [Abstract][Full Text] [Related]
9. Effect of propranolol on hepatic and systemic hemodynamics in dogs with chronic bile duct ligation.
Willems B; Villeneuve JP; Huet PM
Hepatology; 1986; 6(1):92-7. PubMed ID: 3484714
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of chronic tetrandrine and propranolol administration on portal hypertensive rats.
Huang YT; Liu TB; Lin HC; Yang MC; Hong CY
Pharmacology; 1997 May; 54(5):225-31. PubMed ID: 9380768
[TBL] [Abstract][Full Text] [Related]
11. The pharmacological approach to reverse portal hypertention and hepatic schistosomal fibrosis in Egypt, control experimental study.
Helmy AH; Abdel-Hady AA; el-Shanawany F; Hammam O; Abdel-Hady A
J Egypt Soc Parasitol; 2005 Dec; 35(3):731-50. PubMed ID: 16333884
[TBL] [Abstract][Full Text] [Related]
12. Sequential observation of pathomorphological alterations in liver of experimental murine schistosomiasis mansoni.
Bolarin DM; Phil D
Acta Morphol Hung; 1991; 39(3):169-75. PubMed ID: 1818475
[TBL] [Abstract][Full Text] [Related]
13. Propranolol for portal hypertension. Evaluation of therapeutic response by direct measurement of portal vein pressure.
Rector WG
Arch Intern Med; 1985 Apr; 145(4):648-50. PubMed ID: 3985727
[TBL] [Abstract][Full Text] [Related]
14. Effect of propranolol on hepatic blood flow in normal and portal hypertensive rats.
Hillon P; Blanchet L; Lebrec D
Clin Sci (Lond); 1982 Jul; 63(1):29-32. PubMed ID: 7083761
[TBL] [Abstract][Full Text] [Related]
15. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
Agasti AK; Mahajan AU; Phadke AY; Nathani PJ; Sawant P
J Dig Dis; 2013 May; 14(5):266-71. PubMed ID: 23280243
[TBL] [Abstract][Full Text] [Related]
16. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis.
Feu F; Bordas JM; Luca A; García-Pagán JC; Escorsell A; Bosch J; Rodés J
Hepatology; 1993 Nov; 18(5):1082-9. PubMed ID: 8225212
[TBL] [Abstract][Full Text] [Related]
17. Gastro-vascular and micro-vascular changes in chronic murine schistosomiasis mansoni-response to propranolol.
el-Aggan HA; el-Gebaly WM; Khedr MM
J Egypt Soc Parasitol; 1992 Aug; 22(2):415-23. PubMed ID: 1500782
[TBL] [Abstract][Full Text] [Related]
18. Effects of propranolol on portal hemodynamics in patients with chronic liver disease.
Ohnishi K; Nakayama T; Saito M; Hatano H; Tsukamoto T; Terabayashi H; Sugita S; Wada K; Nomura F; Koen H
Am J Gastroenterol; 1985 Feb; 80(2):132-5. PubMed ID: 3881933
[TBL] [Abstract][Full Text] [Related]
19. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
20. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects.
Vorobioff J; Picabea E; Gamen M; Villavicencio R; Bordato J; Bessone F; Tanno H; Palazzi J; Sarano H; Pozzoli L
Hepatology; 1993 Sep; 18(3):477-84. PubMed ID: 8359793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
